Clinical trial
Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure…
NCT00426712 · Dynavax Technologies Corporation, Industry · Completed
Key facts
| NCT number | NCT00426712 |
|---|---|
| Title | Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients |
| Official title | A Phase 1, Randomized, Observer-blind, Dose-escalating Study in Adult End-stage Renal Failure Patients to Explore the Safety, Tolerability, Pharmacokinetics and Immune Response to Recombinant Hepatitis B Virus Surface Antigen (rHBsAg) Co-administered With Dynavax Immunostimulatory Phosphorothioate… |
| Lead sponsor | Dynavax Technologies Corporation, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Biological |
| Interventions | 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant) |
| Enrollment | 42 |
| Start date | Jan 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Jan 25, 2007 |
| Last update posted | Mar 20, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: